Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries

dc.authorid0000-0002-6692-3874
dc.authorid0000-0001-8166-1182
dc.authorid0000-0003-0748-0839
dc.authorid0000-0002-3073-6890
dc.authorid0000-0003-4776-5601
dc.authorid0000-0002-0121-9683
dc.authorid0000-0001-7063-3354
dc.contributor.authorPalafox, Benjamin
dc.contributor.authorMcKee, Martin
dc.contributor.authorBalabanova, Dina
dc.contributor.authorAlHabib, Khalid F.
dc.contributor.authorAvezum, Alvaro Jr
dc.contributor.authorBahonar, Ahmad
dc.contributor.authorIsmail, Noorhassim
dc.date.accessioned2025-05-10T19:34:24Z
dc.date.issued2016
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground: Effective policies to control hypertension require an understanding of its distribution in the population and the barriers people face along the pathway from detection through to treatment and control. One key factor is household wealth, which may enable or limit a household's ability to access health care services and adequately control such a chronic condition. This study aims to describe the scale and patterns of wealth-related inequalities in the awareness, treatment and control of hypertension in 21 countries using baseline data from the Prospective Urban and Rural Epidemiology study. Methods: A cross-section of 163,397 adults aged 35 to 70 years were recruited from 661 urban and rural communities in selected low-, middle- and high-income countries (complete data for this analysis from 151,619 participants). Using blood pressure measurements, self-reported health and household data, concentration indices adjusted for age, sex and urban-rural location, we estimate the magnitude of wealth- related inequalities in the levels of hypertension awareness, treatment, and control in each of the 21 country samples. Results: Overall, the magnitude of wealth- related inequalities in hypertension awareness, treatment, and control was observed to be higher in poorer than in richer countries. In poorer countries, levels of hypertension awareness and treatment tended to be higher among wealthier households; while a similar pro-rich distribution was observed for hypertension control in countries at all levels of economic development. In some countries, hypertension awareness was greater among the poor (Sweden, Argentina, Poland), as was treatment (Sweden, Poland) and control (Sweden). (Continued on next page) Conclusion: Inequality in hypertension management outcomes decreased as countries became richer, but the considerable variation in patterns of wealth-related inequality - even among countries at similar levels of economic development - underscores the importance of health systems in improving hypertension management for all. These findings show that some, but not all, countries, including those with limited resources, have been able to achieve more equitable management of hypertension; and strategies must be tailored to national contexts to achieve optimal impact at population level.
dc.description.sponsorshipUK Economic and Social Research Council [ES/L014696/1]; Marion Burke Chair of the Heart and Stroke Foundation of Canada; Population Health Research Institute; Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario; Astra Zeneca (Canada); Sanofi-Aventis (France and Canada); Boehringer Ingelheim (Germany Canada); Servier; GSK; Argentina: Fundacion ECLA; Bangladesh: Independent University, Bangladesh; Bangladesh: Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada; Canada: Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de la Frontera; China: National Center for Cardiovascular Diseases; Colombia: Colciencias [6566-04-18062]; Colombia: Fundacion Oftalmologica de Santander; India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia [100 - IRDC/BIOTEK 16/6/21 (13/2007), 07-05-IFN-BPH 010]; Malaysia: Ministry of Higher Education of Malaysia [600 - RMI/LRGS/5/3 (2/2011)]; Malaysia: Universiti Teknologi MARA; Malaysia: Universiti Kebangsaan Malaysia [UKM-Hejim-Komuniti-15-2010]; occupied Palestinian territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), occupied Palestinian territory; International Development Research Centre (IDRC), Canada; Philippines: Philippine Council for Health Research & Development (PCHRD); Poland: Polish Ministry of Science and Higher Education [290/W-PURE/2008/0]; Poland: Wroclaw Medical University; Saudi Arabia: Saudi Heart Association; Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia [RG - 1436-013]; South Africa: The North-West University; South Africa: SANPAD (SA and Netherlands Programme for Alternative Development); South Africa: National Research Foundation; South Africa: Medical Research Council of SA; South Africa: The SA Sugar Association (SASA); South Africa: Faculty of Community and Health Sciences (UWC); Sweden: AFA Insurance; Sweden: Swedish Council for Working Life and Social Research; Sweden: King Gustaf V's and Queen Victoria's Freemasons Foundation; Sweden: Swedish Heart and Lung Foundation; Sweden: Swedish Research Council; Sweden: Swedish State under (LakarUtbildningsAvtalet), Agreement; Sweden: Vastra Gotaland Region (FOUU); TURKEY: Metabolic Syndrome Society; TURKEY: Astra Zeneca, Turkey; TURKEY: Sanofi Aventis, Turkey; UAE: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences; UAE: Dubai Health Authority, Dubai UAE; ESRC [ES/L014696/1] Funding Source: UKRI
dc.description.sponsorshipThe UK Economic and Social Research Council funded MM, DB and BP for these analyses through a grant (number ES/L014696/1) under its Secondary Data Analysis Initiative scheme. SY is funded by the Marion Burke Chair of the Heart and Stroke Foundation of Canada.The main PURE study and its components are funded by the Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario and through unrestricted grants from several pharmaceutical companies [with major contributions from Astra Zeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany & Canada), Servier, and GSK], and additional contributions from Novartis and King Pharma and from various national or local organizations in participating countries.These include: Argentina: Fundacion ECLA; Bangladesh: Independent University, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de la Frontera; China: National Center for Cardiovascular Diseases; Colombia: Colciencias, Grant number: 6566-04-18062 and Fundacion Oftalmologica de Santander; India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia Grant Nbr 100 - IRDC/BIOTEK 16/6/21 (13/2007), Grant Number 07-05-IFN-BPH 010, Ministry of Higher Education of Malaysia Grant Nbr 600 - RMI/LRGS/5/3 (2/2011), Universiti Teknologi MARA, Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010); occupied Palestinian territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), occupied Palestinian territory; International Development Research Centre (IDRC), Canada; Philippines: Philippine Council for Health Research & Development (PCHRD); Poland: Polish Ministry of Science and Higher Education grant Nr 290/W-PURE/2008/0, Wroclaw Medical University; Saudi Arabia: Saudi Heart Association. The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (Research group number: RG - 1436-013); South Africa: The North-West University, SANPAD (SA and Netherlands Programme for Alternative Development), National Research Foundation, Medical Research Council of SA, The SA Sugar Association (SASA), Faculty of Community and Health Sciences (UWC); Sweden: AFA Insurance, Swedish Council for Working Life and Social Research, King Gustaf V's and Queen Victoria's Freemasons Foundation, Swedish Heart and Lung Foundation, Swedish Research Council, Grant from the Swedish State under (LakarUtbildningsAvtalet), Agreement, Grant from the Vastra Gotaland Region (FOUU); TURKEY: Metabolic Syndrome Society, Astra Zeneca, Turkey, Sanofi Aventis, Turkey; UAE: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences and Dubai Health Authority, Dubai UAE. The funders of the study had no role in its design, data collection, data analysis, data interpretation, or writing of the report. The corresponding and lead (MM and BP) authors had full access to all the data in the study and all authors had final responsibility for the decision to submit for publication. Acknowledgments and complete list of investigators in the Prospective Urban Rural Epidemiologic (PURE) study are provided in Additional file 10.
dc.identifier.doi10.1186/s12939-016-0478-6
dc.identifier.issn1475-9276
dc.identifier.pmid27931255
dc.identifier.scopus2-s2.0-85008698013
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1186/s12939-016-0478-6
dc.identifier.urihttps://hdl.handle.net/20.500.14730/8482
dc.identifier.volume15
dc.identifier.wosWOS:000391406700001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofInternational Journal For Equity in Health
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectGlobal health
dc.subjectHypertension
dc.subjectSocioeconomic factors
dc.subjectHealthcare disparities
dc.titleWealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
8482.pdf
Boyut:
804.81 KB
Biçim:
Adobe Portable Document Format